title: Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers.
abstract: Quinupristin/dalfopristin (Q/D) is a novel streptogramin antibiotic for the treatment of severe gram-positive infections. The purpose of this open, nonrandomized, parallel-group, phase I trial was to evaluate Q/D pharmacokinetics after single and repeated doses under the two different dosing regimens corresponding to the effective doses and to evaluate tolerability. Two groups of 10 healthy volunteers received multiple 1-hour intravenous infusions of 7.5 mg/kg Q/D either every 8 or 12 hours for 4 or 5 days, respectively. Plasma concentrations of Q, D, and metabolites were determined using high-performance liquid chromatography and selective microbiological assays. The two regimens q8h and q12h lead to the same disposition profile after single and repeated administration. Single-dose data confirmed the high plasma clearances of Q and D (about 0.90 l/h/kg) obtained previously. Unchanged drugs were the main components in plasma, with each of the three metabolites representing about 20% (in terms of the AUC ratio) of the parent drugs. Comparable steady-state concentrations were reached from day 2 of both regimens. A similar moderate increase in Cmax and AUC (about 20%) of parent drugs was observed between the first and last day of treatment. This phenomenon, which was also observed for the metabolites, was not expected considering the short terminal disposition half-lives of the parent drugs and trough plasma concentrations of all components mostly below the limits of quantitation at steady state, whatever the dosing regimen. The clearances of parent drugs at steady state were about 20% lower as compared with that observed following the first drug administration (statistically significant difference). No trend suggesting a treatment effect on any laboratory parameter, vital signs, or electrocardiographic parameters was identified. However, 80% of subjects reported venous adverse events probably related to treatment.
authors: Aventis Pharmaceuticals, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France.
authors: P
authors: P
authors: Chevalier
authors: J
authors: J
authors: Rey
authors: O
authors: O
authors: Pasquier
authors: R
authors: R
authors: Rouzier-Panis
authors: N
authors: N
authors: Harding
authors: G
authors: G
authors: Montay
mesh_terms: D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D001681:Biological Assay; D002851:Chromatography, High Pressure Liquid; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D006094:Gram-Positive Bacteria / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D017192:Skin Diseases, Bacterial / Q000382:microbiology; D013997:Time Factors; D014769:Virginiamycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*
chemical_list: D014769:Virginiamycin; C062940:quinupristin-dalfopristin